1QTI image
Deposition Date 1999-06-28
Release Date 1999-12-29
Last Version Date 2024-10-09
Entry Detail
PDB ID:
1QTI
Keywords:
Title:
Acetylcholinesterase (E.C.3.1.1.7)
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
2.50 Å
R-Value Free:
0.23
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 31 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:ACETYLCHOLINESTERASE
Gene (Uniprot):ache
Chain IDs:A
Chain Length:537
Number of Molecules:1
Biological Source:Torpedo californica
Ligand Molecules
Primary Citation
Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs
Proteins 42 182 191 (2001)
PMID: 11119642 DOI: 10.1002/1097-0134(20010201)42:2<182::AID-PROT50>3.0.CO;2-1

Abstact

The 3D structure of a complex of the anti-Alzheimer drug galanthamine with Torpedo californica acetylcholinesterase is reported. Galanthamine, a tertiary alkaloid extracted from several species of Amarylidacae, is so far the only drug that shows a dual activity, being both an acetylcholinesterase inhibitor and an allosteric potentiator of the nicotinic response induced by acetylcholine and competitive agonists. The X-ray structure, at 2.5A resolution, shows an unexpected orientation of the ligand within the active site, as well as unusual protein-ligand interactions. The inhibitor binds at the base of the active site gorge, interacting with both the acyl-binding pocket and the principal quaternary ammonium-binding site. However, the tertiary amine group of galanthamine does not directly interact with Trp84. A docking study using the program AUTODOCK correctly predicts the orientation of galanthamine in the active site. The docked lowest-energy structure has a root mean square deviation of 0.5A with respect to the corresponding crystal structure of the complex. The observed binding mode explains the affinities of a series of structural analogs of galanthamine and provides a rational basis for structure-based drug design of synthetic derivatives with improved pharmacological properties. Proteins 2001;42:182-191.

Legend

Protein

Chemical

Disease

Primary Citation of related structures